🇺🇸 FDA
Pipeline program

P2Y12 antagonist monotherapy

3-2017-0230

Unknown small_molecule completed

Quick answer

P2Y12 antagonist monotherapy for Coronary Artery Disease is a Unknown program (small_molecule) at Vera Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Vera Therapeutics
Indication
Coronary Artery Disease
Phase
Unknown
Modality
small_molecule
Status
completed

Clinical trials